[go: up one dir, main page]

MX2019004963A - Conjugados y particulas especificos del sstr y formulaciones de los mismos. - Google Patents

Conjugados y particulas especificos del sstr y formulaciones de los mismos.

Info

Publication number
MX2019004963A
MX2019004963A MX2019004963A MX2019004963A MX2019004963A MX 2019004963 A MX2019004963 A MX 2019004963A MX 2019004963 A MX2019004963 A MX 2019004963A MX 2019004963 A MX2019004963 A MX 2019004963A MX 2019004963 A MX2019004963 A MX 2019004963A
Authority
MX
Mexico
Prior art keywords
particles
conjugates
formulations
sstr
methods
Prior art date
Application number
MX2019004963A
Other languages
English (en)
Inventor
Lim Soo Patrick
Sweryda-Krawiec Beata
R Shinde Rajesh
G Alargova Rossitza
Alland Leila
SEARS Chris
Original Assignee
Tarveda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarveda Therapeutics Inc filed Critical Tarveda Therapeutics Inc
Publication of MX2019004963A publication Critical patent/MX2019004963A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Se han disenado conjugados de un agente activo tal como DM1 unido a una fracción dirigida, tal como una fraccion de enlace al receptor de somatostatina, a traves de un enlazador, y particulas que comprenden dichos conjugados. Dichos conjugados y particulas pueden proporcionar una administracion temporoespacial mejorada del agente activo, una mejor biodistribucion y penetracion en el tumor y/o una disminucion de la toxicidad. Se proporcionan metodos para hacer los conjugados, las particulas y las formulaciones de los mismos. Se proporcionan metodos para administrar las formulaciones a un sujeto que lo necesite, por ejemplo, para tratar o prevenir el cancer.
MX2019004963A 2016-10-28 2017-10-27 Conjugados y particulas especificos del sstr y formulaciones de los mismos. MX2019004963A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414481P 2016-10-28 2016-10-28
PCT/US2017/058701 WO2018081521A1 (en) 2016-10-28 2017-10-27 Sstr-targeted conjugates and particles and formulations thereof

Publications (1)

Publication Number Publication Date
MX2019004963A true MX2019004963A (es) 2019-09-26

Family

ID=62024057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004963A MX2019004963A (es) 2016-10-28 2017-10-27 Conjugados y particulas especificos del sstr y formulaciones de los mismos.

Country Status (12)

Country Link
US (2) US11213590B2 (es)
EP (1) EP3532104A4 (es)
JP (2) JP2019532091A (es)
KR (1) KR20190075938A (es)
CN (1) CN109890423A (es)
AU (1) AU2017348313B2 (es)
CA (1) CA3039065A1 (es)
IL (2) IL299532A (es)
MX (1) MX2019004963A (es)
SG (1) SG11201903431SA (es)
TW (1) TW201828992A (es)
WO (1) WO2018081521A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
AU2018386304B2 (en) * 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CA3100216A1 (en) * 2018-06-01 2019-12-05 Tarveda Therapeutics, Inc. Combination therapy
KR20210102874A (ko) * 2018-10-12 2021-08-20 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. 방사성 표지된 gprp 길항제 및 계면활성제를 포함하는 약학적 조성물
SG11202110249SA (en) * 2019-03-18 2021-10-28 Univ Columbia Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof
EP3989941A4 (en) * 2019-06-25 2023-05-10 Tva (Abc), Llc SSTR-TARGETING CONJUGATES AND RELATED FORMULATIONS
WO2022174171A1 (en) * 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
WO2022232124A1 (en) * 2021-04-26 2022-11-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted alpha particle therapy for somatostatin receptor 2 positive neuroendocrine tumors and metastases
CN114748481B (zh) * 2022-05-12 2023-12-05 中国人民解放军海军军医大学 特罗司他马尿酸盐在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
TW202540073A (zh) * 2023-11-30 2025-10-16 大陸商輻聯科技香港有限公司 靶向ｓｓｔｒ受體的放射性化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998154A (en) * 1995-07-07 1999-12-07 The University Of Texas System Somatostatin receptor peptide antigens and antibodies
US7666424B2 (en) * 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20070025910A1 (en) * 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
CA2724534A1 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
AU2012240448A1 (en) * 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
AU2015212418B2 (en) 2014-01-29 2020-01-23 Cosmo Technologies Limited Liquid composition in the form of emulsion or microemulsion for rectal administration containing at least one dye, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3316863A4 (en) 2015-06-30 2019-02-13 Tarveda Therapeutics, Inc. DIRECTED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Also Published As

Publication number Publication date
CA3039065A1 (en) 2018-05-03
AU2017348313A1 (en) 2019-04-18
IL265770A (en) 2019-06-30
US11213590B2 (en) 2022-01-04
JP2023010992A (ja) 2023-01-20
JP2019532091A (ja) 2019-11-07
SG11201903431SA (en) 2019-05-30
EP3532104A4 (en) 2020-06-24
CN109890423A (zh) 2019-06-14
WO2018081521A1 (en) 2018-05-03
AU2017348313B2 (en) 2021-10-21
EP3532104A1 (en) 2019-09-04
US20190262460A1 (en) 2019-08-29
TW201828992A (zh) 2018-08-16
IL299532A (en) 2023-02-01
KR20190075938A (ko) 2019-07-01
US20220054647A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
HK1259311A1 (zh) Sstr靶向綴合物及其顆粒和製劑
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
Kota et al. Pancreatic cancer: Stroma and its current and emerging targeted therapies
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
MY172519A (en) Solid polymeric controlled release nanoparticle
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016046793A3 (en) Radiopharmaceutical conjugate of a metabolite and an epr agent, for targeting tumour cells
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
NZ701573A (en) Carriers for improved drug delivery
SG11201906554RA (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
MY183480A (en) Site-specific conjugation of linker drugs to antibodies and resulting adcs
NZ746680A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MY166014A (en) Combination therapy methods for treating proliferative diseases
NZ710729A (en) Amatoxin derivatives
WO2011002852A3 (en) Pro-drug complexes and related methods of use
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
GB2538023A (en) Targeted drug conjugates
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates